GSK slides as vaccine weakness, turnaround doubts overshadow Q3 beat
28/10/2026 10:41
BUZZ-GSK slides as vaccine weakness, turnaround doubts overshadow Q3 beat ** Shares of GSK GSK.L down 5.5% at 1,817 pence, on track for worst day since April 2025 if losses hold
** GSK beat third-quarter sales and profit expectations, helped by demand for new and specialty medicines
** But vaccines sales fell 2% to £2.58 billion
** Asthma drug Exdensur, which has been on market for just under a year, missed expectations
** Investors remain unconvinced by drugmaker's pipeline expansion plans and a £1.9 billion cost-savings drive announced in July
** GSK reaffirms 2026 guidance
** Stock has fallen about 0.5% YTD
(Reporting by Yamini Kalia and Sri Hari N S in Bengaluru)